Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting

Publication date: January 2019Source: European Journal of Surgical Oncology, Volume 45, Issue 1Author(s): Martina Imbimbo, Jean-Michel Maury, Marina Garassino, Nicolas Girard, Monika Hackl, Elizabeth Van Eycken, Kris Henau, Nadya Dimitrova, Mario Sekerija, Ladislav Dušek, Margit Mägi, Nea Malila, Maarit Leinonen, Michel Velten, Xavier Troussard, Veronique Bouvier, Anne-Valérie Guizard, Anne-Marie Bouvier, Patrick Arveux, Marc MaynadiéAbstractThe management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of databases, translational research programs, and clinical trials. Access to innovative strategies represents a major challenge, as there is a lack of funding for clinical research in rare cancers and their rarity precludes the design of robust clinical trials that could lead to specific approval of drugs. In this context, patient-centered initiatives, such as the establishment of dedicated networks, are warranted. International societies, such as IMIG (International Mesothelioma Interest Group) and ITMIG (International Thymic Malignancy Interest Group) provide infrastructure for global collaboration, and there are many advantages to having strong regional groups working on the same issues. There may be regional differences in risk factors, susceptibility, management and ou...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research

Related Links:

CONCLUSIONS: The matrices and the questionnaire have a great diagnostic performance which seems interesting for a use as a screening tool for occupational exposures. These results have yet to be confirmed by large-scale studies. PMID: 31727556 [PubMed - as supplied by publisher]
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
Publication date: Available online 14 November 2019Source: European Journal of Surgical OncologyAuthor(s): Aditi Bhatt, Yutaka Yonemura, Sanket Mehta, Nazim Benzerdjeb, Praveen Kammar, Loma Parikh, Mita Y. Shah, Sakina Shaikh BHMS, Aruna Prabhu, Suniti Mishra, Snita Sinukumar, Vahan Kepenekian, Naoual Bakrin, Guillaume Passot, Olivier GlehenAbstractBackgroundThe aim was to study the patterns of target region (greater omentum, lesser omentum, falciform and umbilical round ligament) involvement in patients undergoing cytoreductive surgery (CRS) from various primary tumors, factors affecting involvement and implications on su...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Malignant mesothelioma has become the latest deadly cancer linked directly to the rescue, recovery and cleanup efforts following the 9/11 terrorist attack on New York City in 2001. The long-running threat has come to fruition. Eighteen years after Manhattan was engulfed in the asbestos-laced, toxic cloud of dust — caused primarily by the World Trade Center destruction — the first death from pleural mesothelioma attributed to 9/11 has been recorded. Nick Ursta, 52, from the southwestern part of Pennsylvania, died after a year-long battle with the rare cancer. Ursta, a construction worker and fireman by trade, w...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Abstract In an editorial in an earlier issue of this journal, Johanson &Tinnerberg (1) expressed serious and well-founded concern over the large number of future occupational cancer cases that will result if exposures for a number of substances are not reduced below the so-called "binding occupational exposure limit values" (BOELV) issued by the EU (2). The balance between what is perceived as possible to comply with and the foreseeable health gain when setting BOELV is further discussed in a letter to the Editor by Cherrie (3). This debate raises several important aspects of how to protect workers f...
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Authors: Tags: Scand J Work Environ Health Source Type: research
The U.S. Environmental Protection Agency is leaving the Libby Asbestos Superfund site, but that doesn’t mean the job is finished. It’s just changing hands. The Montana Department of Environmental Quality will assume the oversight role of the Superfund site, which was part of the longest-running, man-made environmental disaster in American history. The EPA spent almost two decades decontaminating Libby and nearby Troy, Montana, a massive project stemming from the vermiculite mine operation that once spread asbestos dust throughout the region, sickening both miners and residents throughout Lincoln County. More th...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The Miami Cancer Institute on Thursday will begin using the innovative Tumor Treating Fields device for patients with malignant pleural mesothelioma. It is the first new treatment approved for mesothelioma by the U.S. Food and Drug Administration in more than 15 years. “This is actually pretty exciting for us,” Dr. Rupesh Kotecha, the radiation oncologist who will oversee the treatment protocol in Miami, told The Mesothelioma Center at Asbestos.com. “It’s another tool in our armamentarium. It’s something we can offer patients that has shown a real benefit.” The noninvasive Tumor Treating...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
CONCLUSIONS These results highlight the roles of baicalin in inhibiting cell growth, migration, and invasion of mesothelioma cells while increasing apoptosis and sensitizing cells to chemotherapeutic agents through the PI3K/AKT/mTOR signaling pathway, which indicates that baicalin could be a useful drug for mesothelioma therapy. PMID: 31670317 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Image-based response assessment is often used as a surrogate for the efficacy of a treatment in patients. The radiological response assessment in patients with malignant pleural mesothelioma (MPM) is notoriously difficult, despite changes in the scoring system, modified Response Evaluation Criteria in Solid Tumors (modified RECIST). The current clinical method for tumor response assessment in mesothelioma is the modified RECIST guideline, which calls for two linear measurements of tumor thickness to be summed from each of three axial sections, primarily in computed tomography (CT) scans.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Although malignant mesothelioma (MM) is rare among thoracic malignancies, approximately 1500 and 3000 patients are newly diagnosed each year in Japan and the United States [1], respectively. Treatment of MM, including surgery, radiotherapy, and chemotherapy, is recommended according to stage, performance status, pulmonary function, complications, and patient preference. First-line chemotherapy for advanced MM involves a combination of cisplatin and pemetrexed as the standard treatment. Although this combination has been proven to prolong survival over cisplatin alone in a phase III trial (12.1 months vs.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractBackgroundProjections based on regulations curtailing asbestos use in the USA suggest that peak incidence of pleural mesothelioma would occur between 2000 and 2005 and then decline. We analyzed the National Cancer Database (NCDB) to assess current trends in disease incidence, patient demographics, cancer treatment, and survival.MethodsThe NCDB was queried to identify patients diagnosed with pleural mesothelioma from 2004 through 2014. Clinical and pathologic characteristics, treatments, and survival were analyzed. Risk factors for death were identified by multivariable Cox regression.ResultsA total of 20,988 patien...
Source: World Journal of Surgery - Category: Surgery Source Type: research
More News: Academia | Asbestosis | Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Funding | Mesothelioma | Surgery